Home Newsfeeds Goldman Sachs Maintains Neutral on Twist Bioscience, Lowers Price Target to $43

Goldman Sachs Maintains Neutral on Twist Bioscience, Lowers Price Target to $43

Goldman Sachs analyst Matthew Sykes maintains Twist Bioscience (NASDAQ:TWST) with a Neutral and lowers the price target from $50 to $43.

byBenzinga Newsdesk

February 6, 2023

1 minute read

Goldman Sachs analyst Matthew Sykes maintains Twist Bioscience (NASDAQ:TWST) with a Neutral and lowers the price target from $50 to $43.

This Online Training To Facilitate A Psychedelic Therapy Is Free – Check Out Cybin’s New Offer

By Lara Goldstein

April 12, 5:31 PM

Cybin Inc. (NYSE: CYBN), a clinical-stage biopharma company developing innovative psychedelic-based treatment options, is launching a free online facilitation training course.

CYBN

CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare

By Jelena Martinovic

September 21, 1:08 PM

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporation as the sole agent and sole book-runner on a "best efforts" agency basis in connection with a marketed private placement offering of units of the company

CSE:INNO

Chemed Corporation Announces The Retirement Of CFO David P. Williams On December 31, 2023

By Benzinga Newsdesk

November 3, 4:19 PM

Chemed Corporation (NYSE:CHE) – After more than three decades, Executive Vice President and Chief Financial Officer David P. Williams has announced that he will retire as Chemed's Chief Financial Officer as of December

CHE